Evaluation of a New Agent for Treatment of Advanced Stage Breast Cancer

Phase 2 Completed 65 enrolled Bayer

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate whether treatment with a new drug called ZK-Epothilone (ZK-Epo) in patients with metastatic breast cancer helps to decrease or stop tumor growth.

Timeline

Start: 2006-04
Primary completion: 2008-10
Completion: 2008-11

Publications

Morrow PK, Divers S, Provencher L, Luoh SW, Petrella TM, Giurescu M, Schmelter T, Wang Y, Hortobagyi GN, Vahdat LT. Phase II study evaluating the efficacy and safety of sagopilone (ZK-EPO) in patients with metastatic breast cancer that has progressed following chemotherapy. Breast Cancer Res Treat. 2010 Oct;123(3):837-42. doi: 10.1007/s10549-010-1102-x. Epub 2010 Aug 10.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Sagopilone	Small molecule	16 mg/m2	Intravenous
Subject	Sagopilone	Small molecule	22 mg/m2	Intravenous

Evaluation of a New Agent for Treatment of Advanced Stage Breast Cancer

Summary

Timeline

Publications

Drugs

Indications